Compare stocks

ALK-Abelló A/S is a Danish company specializing in the development and production of allergy immunotherapy products. The company operates within the pharmaceutical industry, providing allergy treatments that include tablets, injections, and drops. Notably, ALK-Abelló focuses on allergy immunotherapy for respiratory allergies, such as allergies to grass, tree pollen, house dust mites, and animal dander. Headquartered in Hørsholm, Denmark, ALK-Abelló serves a global market with a significant presence in Europe and North America. The company's strategic focus on research and development in allergy solutions and its specialized product portfolio underscore its commitment to addressing a critical niche in the healthcare sector.

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.